[
  {
    "ts": "2025-12-09T00:55:00+00:00",
    "headline": "Review Preview: Fed Jitters",
    "summary": "The Fed is expected to cut rates another quarter point on Wednesday. The question is what comes next.",
    "url": "https://www.barrons.com/articles/stocks-today-fed-meeting-lilly-novo-obesity-drugs-6b601766?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "198a16f0-ae71-302b-a099-f59ddc8ea3cc",
      "content": {
        "id": "198a16f0-ae71-302b-a099-f59ddc8ea3cc",
        "contentType": "STORY",
        "title": "Review Preview: Fed Jitters",
        "description": "",
        "summary": "The Fed is expected to cut rates another quarter point on Wednesday. The question is what comes next.",
        "pubDate": "2025-12-09T00:55:00Z",
        "displayTime": "2025-12-09T00:55:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/198a16f0-ae71-302b-a099-f59ddc8ea3cc/review-preview-fed-jitters.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
          "originalWidth": 320,
          "originalHeight": 65,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dzJ1YBP0KGeG_11a2M96gg--~B/aD02NTt3PTMyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e.cf.webp",
              "width": 320,
              "height": 65,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Yw_3eAv_WYSK2a6PV_FD9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stocks-today-fed-meeting-lilly-novo-obesity-drugs-6b601766?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": null,
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T05:37:00+00:00",
    "headline": "2 Potential Stock Splits to Watch for in 2026",
    "summary": "After experiencing incredible rallies during 2025, these two stocks could decide to \"split it\" in 2026.",
    "url": "https://www.fool.com/investing/2025/12/09/2-potential-stock-splits-to-watch-for-in-2026/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "2a3052f3-fa82-3db8-aa60-3b0630a65c12",
      "content": {
        "id": "2a3052f3-fa82-3db8-aa60-3b0630a65c12",
        "contentType": "STORY",
        "title": "2 Potential Stock Splits to Watch for in 2026",
        "description": "",
        "summary": "After experiencing incredible rallies during 2025, these two stocks could decide to \"split it\" in 2026.",
        "pubDate": "2025-12-09T05:37:00Z",
        "displayTime": "2025-12-09T05:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4e13b52455ba13a96deee2a1a87149d8",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Three stock certificates lie atop each other.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M1WhiGZoki_zVP4zjjJYkg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4e13b52455ba13a96deee2a1a87149d8.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6rLIIPVcFU3N9I9Qidjrsw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4e13b52455ba13a96deee2a1a87149d8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/09/2-potential-stock-splits-to-watch-for-in-2026/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-potential-stock-splits-watch-053700968.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ASML"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T10:53:45+00:00",
    "headline": "Wall Street Remains Cautious on Molson Coors Beverage Company (TAP)",
    "summary": "Molson Coors Beverage Company (NYSE:TAP) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On November 21, Piper Sandler lowered its price target for the stock to $50 from $52, while keeping a Neutral rating. The firm said it was revising its price target, taking into account recent developments in […]",
    "url": "https://finance.yahoo.com/news/wall-street-remains-cautious-molson-105345129.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "b17528e6-6805-360b-99fb-0d94fdfa03eb",
      "content": {
        "id": "b17528e6-6805-360b-99fb-0d94fdfa03eb",
        "contentType": "STORY",
        "title": "Wall Street Remains Cautious on Molson Coors Beverage Company (TAP)",
        "description": "",
        "summary": "Molson Coors Beverage Company (NYSE:TAP) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On November 21, Piper Sandler lowered its price target for the stock to $50 from $52, while keeping a Neutral rating. The firm said it was revising its price target, taking into account recent developments in […]",
        "pubDate": "2025-12-09T10:53:45Z",
        "displayTime": "2025-12-09T10:53:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c76d61de5234a894ca2e1680eafc04a8",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Wall Street Remains Cautious on Molson Coors Beverage Company (TAP)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hjffmBkpY7Y.8EHHQpcwVw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/c76d61de5234a894ca2e1680eafc04a8.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.mTCKs1Jw4Sya3ApfOlH8g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c76d61de5234a894ca2e1680eafc04a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-remains-cautious-molson-105345129.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-remains-cautious-molson-105345129.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TAP"
            },
            {
              "symbol": "TAP-A"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T12:45:00+00:00",
    "headline": "Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer",
    "summary": "MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).",
    "url": "https://finance.yahoo.com/news/ability-biotherapeutics-appoints-ang-le-124500304.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "8654457b-10f6-3ef1-b66c-16c9de109f1f",
      "content": {
        "id": "8654457b-10f6-3ef1-b66c-16c9de109f1f",
        "contentType": "STORY",
        "title": "Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer",
        "description": "",
        "summary": "MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).",
        "pubDate": "2025-12-09T12:45:00Z",
        "displayTime": "2025-12-09T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/3ae5467b75c2baa421cf3f0ab3c28d5b",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/i5nsAYtH3_5LzijGf1BhIg--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3ae5467b75c2baa421cf3f0ab3c28d5b.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VNoj2CLtePDlXa5DlK442w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3ae5467b75c2baa421cf3f0ab3c28d5b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ability-biotherapeutics-appoints-ang-le-124500304.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ability-biotherapeutics-appoints-ang-le-124500304.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T12:30:00+00:00",
    "headline": "Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, versus bendamustine plus rituximab (BR), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions. Pirtobrutinib met its primary endpoint demonstrating a reduction in the risk of disease progression or death by 80% (HR=0.20 [95% CI, 0.11-0.37];",
    "url": "https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-significantly-improved-123000965.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "8262707a-9680-38e3-b775-e4c1304b0e70",
      "content": {
        "id": "8262707a-9680-38e3-b775-e4c1304b0e70",
        "contentType": "STORY",
        "title": "Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, versus bendamustine plus rituximab (BR), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions. Pirtobrutinib met its primary endpoint demonstrating a reduction in the risk of disease progression or death by 80% (HR=0.20 [95% CI, 0.11-0.37];",
        "pubDate": "2025-12-09T12:30:00Z",
        "displayTime": "2025-12-09T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-significantly-improved-123000965.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-significantly-improved-123000965.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-09T13:28:00+00:00",
    "headline": "Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the \"Offer\") by Flying Tigers Acquisition Corporation (\"Purchaser\"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares (\"Shares\") of Adverum's common stock in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right",
    "url": "https://finance.yahoo.com/news/lilly-adverum-announce-expiration-completion-132800196.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "1f92cbcc-c03c-3338-be00-e2aea5bede8a",
      "content": {
        "id": "1f92cbcc-c03c-3338-be00-e2aea5bede8a",
        "contentType": "STORY",
        "title": "Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the \"Offer\") by Flying Tigers Acquisition Corporation (\"Purchaser\"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares (\"Shares\") of Adverum's common stock in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right",
        "pubDate": "2025-12-09T13:28:00Z",
        "displayTime": "2025-12-09T13:28:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-adverum-announce-expiration-completion-132800196.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-adverum-announce-expiration-completion-132800196.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ADVM"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]